Press Detail

Biotest AG: Biotest reaches FY 2017 EBIT guidance

Biotest AG / Key word(s): Preliminary Results
Biotest AG: Biotest reaches FY 2017 EBIT guidance

27-Feb-2018 / 10:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Announcement according to Article 17 European Market Abuse Regulation (MAR)

Biotest reaches FY 2017 EBIT guidance

Dreieich, 27 February 2018. According to preliminary and unaudited figures, the Biotest Group generated in the 2017 financial year revenue of EUR 378.1 million in the continuing operations, compared to EUR 408.0 million in the previous year. The main reason for the decline in revenue was the recall of human albumin.

The former EBIT guidance, which included the continuing and discontinued US operations, was reduced on April 26, 2017 after the albumin recall from EUR 46 to EUR 48 million to EUR 16 to EUR 23 million for the 2017 financial year. This guidance, which included the earnings contribution of the US companies, was reached with EUR 18 million.

The EBIT in continuing operations amounted to EUR -9.3 million in the 2017 financial year after EUR 35.2 million in the previous year.

One-off expenses from inventory write-offs, penalties and other costs for the recall of various batches of human albumin as well as legal and consulting fees in connection with the takeover by Tiancheng (Germany) Pharmaceutical Holdings AG, Munich, Germany in the amount of EUR 37.7 million had a negative impact on the EBIT of continuing operations.

Biotest will publish final results for the Financial Year 2017 and the annual report on March 22nd, 2018. The Annual General Meeting of Biotest AG will take place on May 15th, 2018 in Frankfurt /.M.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406

PR contact
Dirk Neumüller
phone: +49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347

27-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this